Axa
SLN

Axa’s Silence Therapeutics SLN Stock Holding History

Axa’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-58,624
Closed -$322K – 1151
2023
Q2 		$322K Sell
58,624
-457,792
-89% -$2.76M ﹤0.01% 993
2023
Q1 		$3.2M Sell
516,416
-125,250
-20% -$1.48M 0.01% 667
2022
Q4 		$9.79M Hold
641,666
– – 0.04% 445
2022
Q3 		$6.44M Hold
641,666
– – 0.03% 527
2022
Q2 		$7.6M Sell
641,666
-20,000
-3% -$243K 0.03% 483
2022
Q1 		$12.6M Hold
661,666
– – 0.04% 438
2021
Q4 		$15.8M Buy
+661,666
New +$15.3M 0.04% 409

Other funds holding SLN

LOAME
Lombard Odier Asset Management (Europe) London, United Kingdom $1.85B AUM 27.05% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MCM
M28 Capital Management Stamford, Connecticut $53.8M AUM 28.63% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Axa's SLN Position: Q3 2023 in Review

Axa sold out of Silence Therapeutics (SLN) in Q3 2023, closing a stake of 58,624 shares — an estimated $322K sold.

Axa first reported a position in SLN in Q4 2021 and held it in 7 quarters. The position peaked at $15.8M in Q4 2021. 28 funds tracked by Wall St. Rank hold SLN as of Q3 2023.

  • Axa reported no remaining Silence Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Axa sold 58,624 Silence Therapeutics shares in Q3 2023, an estimated $322K.
  • Axa first reported a position in Silence Therapeutics in Q4 2021 and held it in 7 quarters.
  • Axa's Silence Therapeutics position peaked at $15.8M in Q4 2021.
  • 28 funds tracked by Wall St. Rank held Silence Therapeutics as of Q3 2023.

Based on Axa's 13F filing for Q3 2023, filed 14 Nov 2023.